Inactive Instrument

All News Synageva Biopharma Corp

Equities

US87159A1034

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2015

Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Synageva Biopharma : Alexion Completes Acquisition of Synageva	23/15/23	BU
Synageva BioPharma : Completes Targeted Enrollment in Phase 1/2 Trial with SBC-103 for Mucopolysaccharidosis IIIB	05/15/05	PR
Synageva BioPharma : Submits Kanuma(TM) (Sebelipase Alfa) Application For LAL Deficiency In Japan	27/15/27	PR
Alexion Pharmaceuticals : to bolster rare disease offering with $8.4 billion deal	07/15/07	RE
Synageva BioPharma : Reports First Quarter 2015 Financial Results and Provides General Business Updates	30/15/30	PR
Synageva BioPharma : Submits Kanuma(TM) (Sebelipase Alfa) Application For LAL Deficiency In Mexico	30/15/30	PR
Synageva BioPharma : Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015	27/15/27	PR
Synageva BioPharma : Reports 2014 Full Year Financial Results	27/15/27	PR
Synageva BioPharma : To Present At The Cowen and Company Health Care Conference	25/15/25	PR
Synageva Biopharma : FDA Accepts BLA Filing For Synageva's Kanuma(TM) (Sebelipase Alfa); Grants Priority Review And Assigns PDUFA Date	23/15/23	PR
Synageva BioPharma : To Host 2014 Fourth Quarter And Full Year Financial Results Conference Call On February 26	19/15/19	PR
Synageva Biopharma : A Look at the Latest Occurrences in the Healthcare Sector: Special Research on Sangamo BioSciences,Seattle Genetics, StemCells, Synageva and VBI Vaccines	19/15/19	PR
Synageva Biopharma : European Patent Issued For Treatment Of LAL Deficiency	18/15/18	PR
Synageva BioPharma : Announces Presentations At 11th Annual World Symposium	11/15/11	PR
Synageva BioPharma : Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted	26/15/26	PR
Synageva BioPharma : Announces Pricing of Public Offering of Common Stock	07/15/07	PR
Synageva BioPharma : Announces A 2.5 Million Share Proposed Public Offering Of Its Common Stock	06/15/06	PR
Synageva BioPharma : Announces New Pipeline Programs And Other Company Progress	05/15/05	PR
Synageva BioPharma : Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA	23/14/23	PR
Synageva BioPharma : To Present At The 33rd Annual J.P. Morgan Healthcare Conference On Monday, January 12, 2015 at 9:00 a.m. PST	17/14/17	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Synageva Biopharma Corp

Equities

US87159A1034

All News

Filters